Generic Byvalson Availability
Last updated on Jul 9, 2025.
Byvalson is a brand name of nebivolol/valsartan, approved by the FDA in the following formulation(s):
BYVALSON (nebivolol hydrochloride; valsartan - tablet;oral)
-
Manufacturer: ABBVIE
Approval date: June 3, 2016
Strength(s): EQ 5MG BASE;80MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Byvalson. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions comprising nebivolol
Patent 7,803,838
Issued: September 28, 2010
Inventor(s): Davis; Eric et al.
Assignee(s): Forest Laboratories Holdings Limited (N/A, BM)Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.
Patent expiration dates:
- August 29, 2026✓
- August 29, 2026
-
Compositions comprising nebivolol
Patent 7,838,552
Issued: November 23, 2010
Inventor(s): Davis; Eric et al.
Assignee(s): Forest Laboratories Holdings Limited (N/A, BM)Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.
Patent expiration dates:
- October 4, 2027✓
- October 4, 2027
More about Byvalson (nebivolol / valsartan)
- Byvalson consumer information
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antihypertensive combinations
- En español
Related treatment guides
Related/similar drugs
Lasix
Lasix is a loop diuretic used to treat fluid retention from heart, liver, or kidney conditions, and ...
Enalapril
Enalapril is used to treat high blood pressure, congestive heart failure and to improve survival ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Valsartan
Valsartan is an angiotensin II receptor blocker (ARB) that may be used to treat high blood pressure ...
Hydrochlorothiazide
HCTZ (hydrochlorothiazide) used to treat high blood pressure (hypertension) and edema. Includes ...
Atenolol
Atenolol is used to treat angina (chest pain) and hypertension (high blood pressure). Learn about ...
Furosemide
Furosemide is a loop diuretic used to treat fluid retention and high blood pressure by increasing ...
Metoprolol
Metoprolol is used to treat angina (chest pain) and hypertension (high blood pressure). Learn about ...
Losartan
Losartan is used to treat high blood pressure (hypertension). It is also used to lower the risk of ...
Lisinopril
Lisinopril is an ACE inhibitor. It is used to treat high blood pressure, congestive heart failure ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.